S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

AVROBIO Stock Forecast, Price & News

-0.05 (-1.37%)
(As of 12/3/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
262,116 shs
Average Volume
443,266 shs
Market Capitalization
$156.70 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AVRO News and Ratings via Email

Sign-up to receive the latest news and ratings for AVROBIO and its competitors with MarketBeat's FREE daily newsletter.



Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.


Morgan Stanley Downgrades AVROBIO (NASDAQ:AVRO) to Equal Weight
November 19, 2021 |  americanbankingnews.com
AVROBIO (NASDAQ:AVRO) Downgraded to Equal Weight at Morgan Stanley
November 19, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$4.43 per share


Net Income
$-119.71 million
Pretax Margin




Free Float
Market Cap
$156.70 million
Not Optionable

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.15 out of 5 stars

Medical Sector

452nd out of 1,390 stocks

Biological Products, Except Diagnostic Industry

68th out of 202 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

AVROBIO (NASDAQ:AVRO) Frequently Asked Questions

Is AVROBIO a buy right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AVROBIO in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" AVROBIO stock.
View analyst ratings for AVROBIO
or view top-rated stocks.

How has AVROBIO's stock been impacted by Coronavirus?

AVROBIO's stock was trading at $18.02 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AVRO shares have decreased by 80.1% and is now trading at $3.59.
View which stocks have been most impacted by COVID-19

When is AVROBIO's next earnings date?

AVROBIO is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for AVROBIO

How were AVROBIO's earnings last quarter?

AVROBIO, Inc. (NASDAQ:AVRO) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.75) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.75).
View AVROBIO's earnings history

What price target have analysts set for AVRO?

8 Wall Street analysts have issued 1-year target prices for AVROBIO's shares. Their forecasts range from $7.00 to $36.00. On average, they expect AVROBIO's share price to reach $21.13 in the next twelve months. This suggests a possible upside of 488.4% from the stock's current price.
View analysts' price targets for AVROBIO
or view top-rated stocks among Wall Street analysts.

Who are AVROBIO's key executives?

AVROBIO's management team includes the following people:
  • Geoff MacKay, President, Chief Executive Officer & Director
  • Erik Ostrowski, Chief Financial Officer & Treasurer
  • Christopher Mason, Chief Scientific Officer
  • Kim Raineri, Chief Manufacturing & Technology Officer
  • Essra Ridha, Chief Medical Officer

What other stocks do shareholders of AVROBIO own?


(AVRO) raised $75 million in an initial public offering (IPO) on Thursday, June 21st 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Cowen and Wells Fargo Securities served as the underwriters for the IPO and Wedbush Securities was co-manager.

What is AVROBIO's stock symbol?

AVROBIO trades on the NASDAQ under the ticker symbol "AVRO."

Who are AVROBIO's major shareholders?

AVROBIO's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (8.28%), BioImpact Capital LLC (1.97%), Millennium Management LLC (1.92%), Geode Capital Management LLC (1.32%), Renaissance Technologies LLC (0.93%) and Morgan Stanley (0.82%). Company insiders that own AVROBIO stock include Christopher Paige, Geoffrey Mackay and Philip J Vickers.
View institutional ownership trends for AVROBIO

Which major investors are selling AVROBIO stock?

AVRO stock was sold by a variety of institutional investors in the last quarter, including Royal Bank of Canada, Point72 Asset Management L.P., Citigroup Inc., Morgan Stanley, Geode Capital Management LLC, New York State Common Retirement Fund, Dimensional Fund Advisors LP, and First Republic Investment Management Inc..
View insider buying and selling activity for AVROBIO
or view top insider-selling stocks.

Which major investors are buying AVROBIO stock?

AVRO stock was purchased by a variety of institutional investors in the last quarter, including BioImpact Capital LLC, Eversept Partners LP, Renaissance Technologies LLC, Millennium Management LLC, Two Sigma Advisers LP, Two Sigma Investments LP, GSA Capital Partners LLP, and BlackRock Inc..
View insider buying and selling activity for AVROBIO
or or view top insider-buying stocks.

How do I buy shares of AVROBIO?

Shares of AVRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AVROBIO's stock price today?

One share of AVRO stock can currently be purchased for approximately $3.59.

How much money does AVROBIO make?

AVROBIO has a market capitalization of $156.70 million. The company earns $-119.71 million in net income (profit) each year or ($2.87) on an earnings per share basis.

How many employees does AVROBIO have?

AVROBIO employs 121 workers across the globe.

What is AVROBIO's official website?

The official website for AVROBIO is www.avrobio.com.

Where are AVROBIO's headquarters?

How can I contact AVROBIO?

AVROBIO's mailing address is ONE KENDALL SQUARE BUILDING 300 SUITE 201, CAMBRIDGE MA, 02139. The company can be reached via phone at (617) 914-8420 or via email at [email protected].

This page was last updated on 12/4/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.